Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IDH1-Mutated Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT04044209
What this trial is testing

The IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Who this might be right for
Myelodysplastic SyndromesAcute Myeloid Leukemia
Yale University
Early research (Phase 1)Ended earlyNCT05814536
What this trial is testing

IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor

Who this might be right for
Cholangiocarcinoma With IDH1 MutationSolid Tumors With IDH1 Mutation
AnHeart Therapeutics Inc. 9
Testing effectiveness (Phase 2)Study completedNCT03914742
What this trial is testing

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Who this might be right for
IDH1 MutationIDH2 MutationRecurrent Glioblastoma+2 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 67
Testing effectiveness (Phase 2)WithdrawnNCT04013880
What this trial is testing

ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid Leukemia+3 more
Vanderbilt-Ingram Cancer Center
Early research (Phase 1)Study completedNCT03127735
What this trial is testing

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)

Who this might be right for
Leukemia, Myeloid, Acute
Bayer 27
Early research (Phase 1)Active Not RecruitingNCT02632708
What this trial is testing

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Who this might be right for
Newly Diagnosed Acute Myeloid Leukemia (AML)Untreated AMLAML Arising From Myelodysplastic Syndrome (MDS)+2 more
Institut de Recherches Internationales Servier 153
Early research (Phase 1)Ended earlyNCT02576665
What this trial is testing

Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)

Who this might be right for
Colorectal CancerTriple Negative Breast CancerPancreatic Cancer+9 more
Tocagen Inc. 21
Early research (Phase 1)Study completedNCT02073994
What this trial is testing

Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

Who this might be right for
CholangiocarcinomaChondrosarcomaGlioma+1 more
Institut de Recherches Internationales Servier 174
Not applicableActive Not RecruitingNCT01358058
What this trial is testing

Proton Radiation Therapy for Gliomas

Who this might be right for
Low Grade GliomaWHO Grade 3 Glioma With IDH1 MutationWHO Grade 3 Glioma With 1p/19q Codeletion
Massachusetts General Hospital 63
Early research (Phase 1)Study completedNCT04176393
What this trial is testing

A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation

Who this might be right for
Relapsed or Refractory Acute Myeloid Leukemia
CStone Pharmaceuticals 30
Testing effectiveness (Phase 2)Looking for participantsNCT06566742
What this trial is testing

Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

Who this might be right for
Myelodysplastic SyndromesChronic Myelomonocytic LeukemiaClonal Cytopenia of Undetermined Significance
M.D. Anderson Cancer Center 15
Early research (Phase 1)Looking for participantsNCT06666712
What this trial is testing

Chronic CED of TPT for Recurrent Malignant Glioma

Who this might be right for
Brain Tumor, RecurrentMalignant Glioma (WHO Grade III or IV)IDH1/IDH2 Mutation
Jeffrey N. Bruce 6
Large-scale testing (Phase 3)Study completedNCT02989857
What this trial is testing

Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)

Who this might be right for
Advanced CholangiocarcinomaMetastatic Cholangiocarcinoma
Institut de Recherches Internationales Servier 187
Early research (Phase 1)Ended earlyNCT04250051
What this trial is testing

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Recurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRecurrent Myeloproliferative Neoplasm+5 more
Northwestern University 2
Testing effectiveness (Phase 2)Looking for participantsNCT06668584
What this trial is testing

A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies

Who this might be right for
Myeloid Malignancies
M.D. Anderson Cancer Center 31
Testing effectiveness (Phase 2)Looking for participantsNCT07607418
What this trial is testing

Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS

Who this might be right for
AML (Acute Myeloid Leukemia)MDS (Myelodysplastic Syndrome)
Ruijin Hospital 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT04278781
What this trial is testing

AG-120 in People With IDH1 Mutant Chondrosarcoma

Who this might be right for
ChondrosarcomaChondrosarcoma, Grade 2Chondrosarcoma, Grade 3+1 more
Memorial Sloan Kettering Cancer Center 6
Early research (Phase 1)Looking for participantsNCT02074839
What this trial is testing

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Who this might be right for
Relapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AMLOther IDH1-mutated Positive Hematologic Malignancies+1 more
Institut de Recherches Internationales Servier 291
Testing effectiveness (Phase 2)Active Not RecruitingNCT04458272
What this trial is testing

DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma

Who this might be right for
WHO Grade II Glioma
Daiichi Sankyo Co., Ltd. 25
Large-scale testing (Phase 3)Looking for participantsNCT06387069
What this trial is testing

Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Hutchmed 316
Next Page